Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Training Personnel in CLD Procedures – V 2.0

Posted on By


Biosimilars: SOP for Training Personnel in CLD Procedures – V 2.0


Standard Operating Procedure for Training Personnel in Cell Line Development Procedures

Department Biosimilars
SOP No. SOP/BS/057/2025
Supersedes SOP/BS/057/2022
Page No. Page 1 of 10
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a standardized training process for all personnel involved in Cell Line Development (CLD) operations in biosimilar manufacturing, ensuring technical competence, regulatory awareness, and compliance with GMP practices.

2. Scope

This SOP applies to newly inducted scientists, technicians, and existing staff in the biosimilar CLD department involved in gene transfection, clone screening, cell bank preparation, and related documentation.

3. Responsibilities

  • Training Coordinator: Designs training calendar, maintains training records, and schedules assessments.
  • Department Head: Approves training plans and ensures availability of subject matter experts (SMEs).
  • Trainee: Attends training sessions, completes evaluations, and follows instructions.

4. Accountability

The Head of Biosimilars is accountable for ensuring all CLD personnel are trained, assessed, and qualified for their assigned tasks as per regulatory expectations.

5. Procedure

5.1 Training Need Identification

  1. Conduct a Training Needs Assessment (TNA) using the Training Matrix (Annexure-1).
  2. Identify personnel based on:
    • Role and function in CLD
    • Previous experience
    • Regulatory or procedural updates

5.2 Training Methods

  1. Use the following formats:
    • Classroom training for theory and SOP reviews
    • Hands-on lab training for procedures like thawing, transfection, and screening
    • On-the-job training (OJT) under supervision
  2. All training materials must be reviewed and approved by QA and department head.

5.3 Training Execution

  1. Schedule training sessions as per Training Calendar (Annexure-2).
  2. Ensure SME or qualified trainer delivers the session and records attendance in Training Log (Annexure-3).
  3. Trainee shall sign the log upon completion of each module.

5.4 Evaluation and Qualification

  1. Post-training assessment to be conducted using written quizzes or practical observation forms.
  2. Minimum passing score is 80% for written and “Satisfactory” for practicals.
  3. Issue Training Completion Certificate (Annexure-4) after successful evaluation.

5.5 Retraining and Continuous Learning

  1. Retraining shall be conducted in the following cases:
    • Annual GMP refresher programs
    • Post-deviation involving human error
    • Major SOP revision
  2. Maintain retraining records with justification and trainer remarks.

5.6 Documentation and Archival

  1. Training logs and certificates shall be filed in the individual employee training file.
  2. Electronic copies to be archived on the QA-secured server with restricted access.

6. Abbreviations

  • CLD: Cell Line Development
  • SME: Subject Matter Expert
  • TNA: Training Needs Assessment
  • OJT: On-the-Job Training

7. Documents

  1. Training Matrix – Annexure-1
  2. Training Calendar – Annexure-2
  3. Training Log – Annexure-3
  4. Training Completion Certificate – Annexure-4

8. References

  • EU GMP Chapter 2 – Personnel
  • ICH Q10 – Pharmaceutical Quality System
  • 21 CFR Part 211.25 – Training of Personnel

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Training Matrix

Employee Name Role Required Training Completed
Ajay Verma Junior Scientist Transfection, MCB Preparation Yes

Annexure-2: Training Calendar

Month Topic Trainer Planned Date Status
May 2025 CLD Documentation SOP Sunita Reddy 10/05/2025 Scheduled

Annexure-3: Training Log

Date Topic Trainee Name Trainer Signature
02/05/2025 ELISA-based Clone Screening Vinay Pawar Dr. Neha Singh

Annexure-4: Training Completion Certificate

Certificate No. CLD/TRN/057/2025
Employee Name Vinay Pawar
Training Module Stable Clone Development
Completion Date 03/05/2025
Trainer Sunita Reddy
Remarks Qualified

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Expanded evaluation criteria and added Annexure for certificate Training System Upgrade
See also  Biosimilars: SOP for Deviation Handling During Clone Development - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Analytical Method Development: Limit Test for Iron and Heavy Metals – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version